Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | RB1 |
Variant | Q121H |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | RB1 Q121H does not lie within any known functional domains of the Rb1 protein (UniProt.org). Q121H has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, May 2024). |
Associated Drug Resistance | |
Category Variants Paths |
RB1 mutant RB1 Q121H |
Transcript | NM_000321.3 |
gDNA | chr13:g.48342697G>T |
cDNA | c.363G>T |
Protein | p.Q121H |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000321.3 | chr13:g.48342697G>T | c.363G>T | p.Q121H | RefSeq | GRCh38/hg38 |
NM_000321 | chr13:g.48342697G>T | c.363G>T | p.Q121H | RefSeq | GRCh38/hg38 |
NM_001407166.1 | chr13:g.48342697G>T | c.363G>T | p.Q121H | RefSeq | GRCh38/hg38 |
NM_000321.2 | chr13:g.48342697G>T | c.363G>T | p.Q121H | RefSeq | GRCh38/hg38 |
NM_001407165.1 | chr13:g.48342697G>T | c.363G>T | p.Q121H | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RB1 mutant | estrogen-receptor positive breast cancer | predicted - resistant | Palbociclib | Phase III | Actionable | In a Phase III trial (PALOMA-3), acquired RB1 mutations were identified in patents with ER-positive, ERBB2 (HER2)-negative breast cancer at the end of treatment in the Faslodex (fulvestrant) plus Ibrance (palbociclib) but not the Faslodex (fulvestrant) plus placebo arm, suggesting a role in conferring resistance to Ibrance (palbociclib) (PMID: 30206110; NCT01942135). | 30206110 |
RB1 mutant | osteosarcoma | sensitive | VCN-01 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, VCN-01 decreased viability of a human RB1-mutant primary osteosarcoma cell line in culture, and inhibited tumor growth and decreased lung metastases in xenograft models (PMID: 26603261). | 26603261 |